PMC:7102591 / 14723-15308 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"469","span":{"begin":37,"end":45},"obj":"Species"},{"id":"470","span":{"begin":59,"end":66},"obj":"Chemical"},{"id":"471","span":{"begin":385,"end":392},"obj":"Chemical"},{"id":"472","span":{"begin":12,"end":21},"obj":"Disease"},{"id":"473","span":{"begin":34,"end":36},"obj":"Disease"}],"attributes":[{"id":"A469","pred":"tao:has_database_id","subj":"469","obj":"Tax:9606"},{"id":"A472","pred":"tao:has_database_id","subj":"472","obj":"MESH:D007239"},{"id":"A473","pred":"tao:has_database_id","subj":"473","obj":"MESH:D001172"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T189","span":{"begin":12,"end":21},"obj":"Disease"},{"id":"T190","span":{"begin":34,"end":36},"obj":"Disease"},{"id":"T192","span":{"begin":561,"end":571},"obj":"Disease"}],"attributes":[{"id":"A189","pred":"mondo_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A190","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0005272"},{"id":"A191","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A192","pred":"mondo_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T111","span":{"begin":280,"end":281},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":34,"end":36},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_73810"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T79","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T80","span":{"begin":164,"end":433},"obj":"Sentence"},{"id":"T81","span":{"begin":434,"end":585},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T61","span":{"begin":34,"end":36},"obj":"Phenotype"}],"attributes":[{"id":"A61","pred":"hp_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}

{"project":"2_test","denotations":[{"id":"32205186-23192911-4826894","span":{"begin":156,"end":158},"obj":"23192911"},{"id":"32205186-29180125-4826895","span":{"begin":159,"end":161},"obj":"29180125"},{"id":"32205186-28298374-4826896","span":{"begin":201,"end":203},"obj":"28298374"},{"id":"32205186-19022409-4826897","span":{"begin":242,"end":244},"obj":"19022409"},{"id":"32205186-22796281-4826898","span":{"begin":248,"end":250},"obj":"22796281"},{"id":"32205186-29592917-4826899","span":{"begin":254,"end":256},"obj":"29592917"},{"id":"32205186-25975452-4826900","span":{"begin":429,"end":431},"obj":"25975452"},{"id":"32205186-23800448-4826901","span":{"begin":581,"end":583},"obj":"23800448"}],"text":"The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61]."}